Olav Bergheim, CEO & President
Mr. Bergheim is the Founder, Chief Executive Officer and President of Metronom Health, Inc. He is also the Founder and Managing Director of Fjord Ventures LLC (www.fjordventures.com).
Fjord Ventures is a life science accelerator company which has several companies in its portfolio which include Adagio Medical, Inc., Allegro Medical, Inc., Anaxiom Corporation, Kato Pharmaceuticals, Inc., Metronom Health, Inc., Orasis Medical, Inc., Otello Medical, Inc., Prelude Corporation, Sonendo, Inc., Volante Diagnostics, Inc. and YAP Therapeutics, Inc. Each of these companies was founded by Mr. Bergheim.
Prior to starting Fjord Ventures, Mr. Bergheim was General Partner of Domain Associates. In 1995, he joined Domain with the charter of forming and providing active management to new life sciences companies. While at Domain, Mr. Bergheim created the Company Creation Initiative which led to the formation of several companies including Chimeric Therapies, Inc.; VenPro; 3F Therapeutics (acquired by Medtronic); Orqis Medical; Vessix Vascular (acquired by Boston Scientific), Volcano Therapeutics (acquired by Phillips); and Glaukos Corporation (NASDAQ: GKOS).
Prior to Domain, Mr. Bergheim spent 18 years in general management positions at Baxter Healthcare Corporation, as Corporate Group Vice President as well as President of Baxter’s Cardiovascular Group (now: Edwards LifeSciences). Previous Baxter positions included President of Immunotherapy Worldwide, President BioTech Europe, and President of Baxter in Germany and General Manager of the Nordic area.